Zur Kurzanzeige

dc.contributor.author
Kaufmann, Stefan H.E.
dc.contributor.author
Dockrell, Hazel M.
dc.contributor.author
Drager, Nick
dc.contributor.author
Ho, Mei M.
dc.contributor.author
McShane, Helen
dc.contributor.author
Neyrolles, Olivier
dc.contributor.author
Ottenhoff, Tom H.M.
dc.contributor.author
Patel, Brij
dc.contributor.author
Roordink, Danielle
dc.contributor.author
Spertini, François
dc.contributor.author
Stenger, Steffen
dc.contributor.author
Thole, Jelle
dc.contributor.author
Verreck, Frank A.W.
dc.contributor.author
Williams, Ann
dc.contributor.author
TBVAC2020 Consortium
dc.date.accessioned
2019-07-03T08:32:24Z
dc.date.available
2017-10-19T02:12:19Z
dc.date.available
2017-10-30T09:58:42Z
dc.date.available
2019-07-03T08:32:24Z
dc.date.issued
2017-10-04
dc.identifier.issn
1664-3224
dc.identifier.other
10.3389/fimmu.2017.01203
en_US
dc.identifier.uri
http://hdl.handle.net/20.500.11850/197748
dc.identifier.doi
10.3929/ethz-b-000197748
dc.description.abstract
TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, TBVAC2020 offers portfolio management that provides selection criteria for entry, gating, and priority settings of novel vaccines at an early developmental stage. The TBVAC2020 consortium coordinated by TBVI facilitates collaboration and early data sharing between partners with the common aim of working toward the development of an effective TB vaccine. Close links with funders and other consortia with shared interests further contribute to this goal.
en_US
dc.format
application/pdf
en_US
dc.language.iso
en
en_US
dc.publisher
Frontiers
en_US
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/
dc.subject
Tuberculosis
en_US
dc.subject
Bacille Calmette-Guérin
en_US
dc.subject
Vaccination
en_US
dc.subject
Biomarker
en_US
dc.subject
Clinical trial
en_US
dc.subject
Portfolio management
en_US
dc.subject
Discovery
en_US
dc.title
TBVAC2020: Advancing tuberculosis vaccines from discovery to clinical development
en_US
dc.type
Review Article
dc.rights.license
Creative Commons Attribution 4.0 International
ethz.journal.title
Frontiers in Immunology
ethz.journal.volume
8
en_US
ethz.journal.abbreviated
Front Immunol
ethz.pages.start
1203
en_US
ethz.size
18 p.
en_US
ethz.version.deposit
publishedVersion
en_US
ethz.identifier.scopus
ethz.publication.place
Lausanne
en_US
ethz.publication.status
published
en_US
ethz.leitzahl
ETH Zürich::00002 - ETH Zürich::00012 - Lehre und Forschung::00007 - Departemente::02030 - Dep. Biologie / Dep. of Biology::02538 - Institut für Molekulare Systembiologie / Institute for Molecular Systems Biology
en_US
ethz.date.deposited
2017-10-19T02:12:23Z
ethz.source
SCOPUS
ethz.eth
yes
en_US
ethz.availability
Open access
en_US
ethz.rosetta.installDate
2017-10-30T09:58:43Z
ethz.rosetta.lastUpdated
2019-07-03T08:32:35Z
ethz.rosetta.versionExported
true
ethz.COinS
ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.atitle=TBVAC2020:%20Advancing%20tuberculosis%20vaccines%20from%20discovery%20to%20clinical%20development&rft.jtitle=Frontiers%20in%20Immunology&rft.date=2017-10-04&rft.volume=8&rft.spage=1203&rft.issn=1664-3224&rft.au=Kaufmann,%20Stefan%20H.E.&Dockrell,%20Hazel%20M.&Drager,%20Nick&Ho,%20Mei%20M.&McShane,%20Helen&rft.genre=article&
 Suchen via SFX

Dateien zu diesem Eintrag

Thumbnail

Publikationstyp

Zur Kurzanzeige